TTR and amyloidosis: In addition to established co-morbidities, a clustering of transthyretin (TTR) amyloidosis in LFLG patients (up to 30% prevalence) can now be reasonably assumed, which may further explain the adverse outcomes observed in comparison with HG AS patients.